Panel : Debating the Therapeutics Utility of PROTACs & Molecular Glues versus Direct Targeting of RAS to Strategies Best-in-Class Therapeutic Interventions

Time: 12:15 pm
day: Day Two Track A AM


• What are the advantages of degrading versus direct targeting?

• What are the additional complexities associated with degrader development?

• How to monitor RAS turnover and the kinetics of degradation?

• What is the combination potential of PROTACs?